

ISSUE @ A GLANCE



Dyslipidaemias in stroke, chronic kidney disease, and aortic stenosis: the new frontiers for cholesterol lowering
F. Crea

2137

CardioPulse

Security in BioMedical Research publications
B. Gaye, S. Khoury, W. Sutter, and X. Jouven

2141

Jennifer A. Doudna and Emmanuelle Charpentier
J. Ozkan

2143

Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence
F. Schoenrath, I.A. Just, V. Falk, and M.Y. Emmert

2145

Introduction to the Department of Cardiology in West China Hospital of Sichuan University
Z.-G. Zhao, J.-J. He, Y. Feng, and M. Chen

2148

Weekly Journal Scan

Modulating the gut microbiome with dietary interventions to reduce cardiometabolic disease risk
G. Liuzzo and L. Galiuto

2152

STATE OF THE ART REVIEW

Dyslipidaemias

How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol

A.D. Karagiannis, A. Mehta, D.S. Dhindsa, S.S. Virani, C.E. Orringer, R.S. Blumenthal, N.J. Stone, and L.S. Sperling

2154

Lipoproteins in chronic kidney disease: from bench to bedside
T. Speer, P.M. Ridker, A. von Eckardstein, S.J. Schunk, and D. Fliser

2170


CLINICAL RESEARCH

Dyslipidaemias

Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study

M. Arnold, J. Schweizer, C.T. Nakas, V. Schütz, L.P. Westphal, C. Inauen, T. Pokorny, A. Luft, A. Leichtle, M. Arnold, A. Bivic, U. Fischer, G.M. De Marchis, L.H. Bonati, M.D. Müller, T. Kahles, K. Nedeltchev, C.W. Cereda, G. Kägi, A. Bustamante, J. Montaner, G. Ntaios, C. Foerch, K. Spanaus, A. von Eckardstein, and M. Katan

2186



Number at risk					
1448	1176	1125	1087	1071	$Lp(a) < 100nmol/l$
285	224	214	210	207	$Lp(a) \geq 100nmol/l$

Editorial

Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly

S. Tsimikas


2197

Dyslipidaemias

Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia

L. Pérez de Isla, G.F. Watts, R. Alonso, J.L. Díaz-Díaz, O. Muñoz-Grijalvo, D. Zambón, F. Fuentes, R. de Andrés, T. Padró, J. López-Miranda, and P. Mata

2201



Editorial

Aortic valve stenosis: the long and winding road
F. Kronenberg

2212

DISCUSSION FORUM

Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis

N. Zhang, G. Tse and T. Liu

2215

The neutrophil-lymphocyte ratio: considerations for clinical application

N.H. Adamstein and P.M. Ridker

2216

CARDIOVASCULAR FLASHLIGHT

Severe calcification of the Achilles' tendon

M.-A. Kawashiri, H. Okada, and H. Tada

2217

Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging

K. Imamoto, Y. Kataoka, H. Hosoda, and T. Noguchi

2218

CORRIGENDUM

Corrigendum to: CaMKII inhibition reduces electrical activation heterogeneities caused by mechanical stretch in the myocardium

2211



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>

www.eurheartj.org